NYSE:NUVB

Nuvation Bio - NUVB Stock Forecast, Price & News

$2.51

+0.06 (+2.45%)

(As of 10/5/2022 02:57 PM ET)

Add

Compare

Today's Range: $2.41
▼
$2.51
50-Day Range: $1.99
▼
$3.13
52-Week Range: $1.92
▼
$10.45

Volume: 39,219 shs
Average Volume: 645,706 shs
Market Capitalization: $547.78 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Nuvation Bio MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 59.4% Upside
$4.00 Price Target
Short Interest: Healthy
5.74% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.53) to ($0.51) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.32 out of 5 stars

Medical Sector

348th out of 1,087 stocks

Pharmaceutical Preparations Industry

156th out of 546 stocks

3.3

Analyst's Opinion

Consensus Rating
Nuvation Bio has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.00, Nuvation Bio has a forecasted upside of 59.4% from its current price of $2.51.
Amount of Analyst Coverage
Nuvation Bio has only been the subject of 4 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
5.74% of the float of Nuvation Bio has been sold short.
Short Interest Ratio / Days to Cover
Nuvation Bio has a short interest ratio ("days to cover") of 7.4.
Change versus previous month
Short interest in Nuvation Bio has recently decreased by 8.00%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Nuvation Bio does not currently pay a dividend.
Dividend Growth
Nuvation Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for NUVB.

N/A

News and Social Media Coverage

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Nuvation Bio insiders have not sold or bought any company stock.
Percentage Held by Insiders
34.75% of the stock of Nuvation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
71.17% of the stock of Nuvation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Nuvation Bio are expected to grow in the coming year, from ($0.53) to ($0.51) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Nuvation Bio is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Nuvation Bio is -5.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Nuvation Bio has a P/B Ratio of 0.73. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Nuvation Bio (NYSE:NUVB) Stock

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.

Receive NUVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter.

NUVB Stock News Headlines

August 10, 2022 | finance.yahoo.com

Nuvation Bio (NYSE:NUVB) Is In A Good Position To Deliver On Growth Plans

August 4, 2022 | finance.yahoo.com

Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update

August 3, 2022 | marketwatch.com

Nuvation Bio to End NUV-422 Program, Cut 35% of Staff >NUVB

August 1, 2022 | msn.com

After FDA Hold, Nuvation Bio Stops NUV-422 Cancer Development Program

August 1, 2022 | seekingalpha.com

Nuvation stock falls as NUV-422 cancer program gets axed, 35% workforce cut

August 1, 2022 | nasdaq.com

Nuvation Bio To Discontinue Clinical Development Of NUV-422

August 1, 2022 | finance.yahoo.com

Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program

July 27, 2022 | finance.yahoo.com

Nuvation Bio Inc. (NUVB) Upgraded to Buy: What Does It Mean for the Stock?

July 18, 2022 | finance.yahoo.com

Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer

July 11, 2022 | markets.businessinsider.com

Short Volatility Alert: Nuvation Bio Inc.

July 5, 2022 | apnews.com

Nuvation Bio, Inc. Investors: Company Investigated by the Portnoy Law Firm

June 30, 2022 | benzinga.com

ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

June 29, 2022 | apnews.com

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm

June 29, 2022 | benzinga.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nuvation Bio Inc. - NUVB

June 27, 2022 | nasdaq.com

Why Nuvation Bio Stock Falling In Pre-market?

June 27, 2022 | finance.yahoo.com

FDA Institutes Partial Hold On Nuvation Bio's Early-Stage Solid Tumor Trial - Read Why

June 27, 2022 | marketwatch.com

Nuvation Bio Study of Lead Product Candidate Put on Partial Clinical Hold by FDA

June 27, 2022 | seekingalpha.com

Nuvation Bio sheds ~14% as FDA imposes partial hold on cancer trial

June 27, 2022 | finance.yahoo.com

Nuvation Bio Announces FDA Partial Clinical Hold for Phase 1 Study of NUV-422 in Solid Tumors

June 4, 2022 | theglobeandmail.com

Instrument Name Nuvation Bio Inc Instrument Symbol (NUVB-N)

May 24, 2022 | nasdaq.com

Buying Power of Binance Coin vs. Nuvation Bio at New 52-Week High

May 9, 2022 | finance.yahoo.com

Nuvation Bio Reports First Quarter 2022 Financial Results and Provides Business Update

May 4, 2022 | benzinga.com

HC Wainwright & Co. Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $14

March 22, 2022 | benzinga.com

BMO Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $12

February 28, 2022 | finance.yahoo.com

Nuvation Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NUVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nuvation Bio and its competitors with MarketBeat's FREE daily newsletter.

NUVB Company Calendar

Last Earnings: 8/04/2022
Today: 10/05/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:NUVB
CUSIP: N/A
CIK: 1811063
Web: www.nuvationbio.com
Phone: 332-208-6102
Fax: N/A
Employees: 64
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $2.50
Forecasted Upside/Downside: +59.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.49)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-86,850,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -14.09%
Return on Assets: -13.56%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 33.58
Quick Ratio: 33.57

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.42 per share
Price / Book: 0.73

Miscellaneous

Outstanding Shares: 218,240,000
Free Float: 142,404,000
Market Cap: $547.78 million
Optionable: Not Optionable
Beta: 0.56

Key Executives

Dr. David T. Hung M.D. (Age 64)
Founder, Pres, CEO & Director
Comp: $1.18M

Ms. Jennifer A. Fox (Age 50)
CFO & Sec.
Comp: $1.01M

Dr. David C. Hanley Ph.D. (Age 52)
Chief Technical Operations Officer
Comp: $497.14k

Dr. Gary Hattersley Ph.D. (Age 55)
Chief Scientific Officer

Ms. Stacy Markel (Age 57)
Chief People Officer

Ms. Melanie Morrison
Sr. VP of Clinical Operations & Program Management

Ms. Kerry A. Wentworth (Age 49)
Chief Regulatory Officer

Dr. David Liu M.D.
Ph.D., Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NUVB Stock - Frequently Asked Questions

Should I buy or sell Nuvation Bio stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nuvation Bio in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" NUVB shares.
View NUVB analyst ratings or view top-rated stocks.
What is Nuvation Bio's stock price forecast for 2022?: 4 equities research analysts have issued 12-month price targets for Nuvation Bio's stock. Their NUVB share price forecasts range from $2.50 to $5.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 59.4% from the stock's current price.
View analysts price targets for NUVB or view top-rated stocks among Wall Street analysts.
How have NUVB shares performed in 2022?: Nuvation Bio's stock was trading at $9.70 at the start of the year. Since then, NUVB stock has decreased by 74.1% and is now trading at $2.51.
View the best growth stocks for 2022 here.
When is Nuvation Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our NUVB earnings forecast.

How were Nuvation Bio's earnings last quarter?: Nuvation Bio Inc. (NYSE:NUVB) posted its quarterly earnings results on Thursday, August, 4th. The company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.03.
What is Nuvation Bio's stock symbol?: Nuvation Bio trades on the New York Stock Exchange (NYSE) under the ticker symbol "NUVB."
How do I buy shares of Nuvation Bio?: Shares of NUVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Nuvation Bio's stock price today?: One share of NUVB stock can currently be purchased for approximately $2.51.
How much money does Nuvation Bio make?: Nuvation Bio (NYSE:NUVB) has a market capitalization of $547.78 million. The company earns $-86,850,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis.
How can I contact Nuvation Bio?: Nuvation Bio's mailing address is 1500 BROADWAY SUITE 1401, NEW YORK NY, 10036. The official website for the company is www.nuvationbio.com. The company can be reached via phone at 332-208-6102 or via email at ir@nuvationbio.com.

This page (NYSE:NUVB) was last updated on 10/5/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial